

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/575,745
				Filing Date	April 9, 2007
				First Named Inventor	Yigal M. Pinto
				Art Unit	1641
				Examiner Name	G. W. Counts
Sheet	1	of	6	Attorney Docket Number	BYG-101

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A1	US-20030032030	02-13-2003	Prolla <i>et al.</i>	
	A2	US-20040110221	06-10-2004	Twine <i>et al.</i>	
	A3	US-20050084915	04-21-2005	Woo	
	A4	US-20050106100	05-19-2005	Harris <i>et al.</i>	
	A5	US-20060019235	01-26-2006	Soen <i>et al.</i>	
	A6	US-20060019890	01-26-2006	Kapoun <i>et al.</i>	
	A7	US-20060141493	06-29-2006	West <i>et al.</i>	
	A8	US-20060246496	11-02-2006	Ahmed <i>et al.</i>	
	A9	US-20060257946	11-16-2006	Ding <i>et al.</i>	
	A10	US-20070082332	04-12-2007	Mendrick <i>et al.</i>	
	A11	US-20070092886	04-26-2007	Tabibiazar <i>et al.</i>	
	A12	US-20070105105	05-10-2007	Clelland <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B1	WO-0157274-A2	08-09-2001	Molecular Dynamics Inc <i>et al.</i>		
	B2	WO-0177389-A2	10-18-2001	Incyte Genomics Inc <i>et al.</i>		
	B3	WO-03031650-A2	04-17-2003	Bayer Ag <i>et al.</i>		
	B4	WO-03071279-A1	08-28-2003	Zarita Biotech Co Ltd <i>et al.</i>		
	B5	WO-2004038376-A2	05-06-2004	Univ Duke <i>et al.</i>		
	B6	WO-2004048933-A2	06-10-2004	Wyeth Corp <i>et al.</i>		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <h1>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h1>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/575,745
				Filing Date	April 9, 2007
				First Named Inventor	Yigal M. Pinto
				Art Unit	1641
				Examiner Name	G. W. Counts
				Attorney Docket Number	BYG-101
Sheet	2	of	6		

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> ( <i># known</i> )	MM-DD-YYYY			
	B7	WO-2004063334-A2	07-29-2004	Gene Logic Inc <i>et al.</i>		
	B8	WO-2004111654-A2	12-23-2004	Ciphergen Biosystems Inc <i>et al.</i>		
	B9	WO-2005023314-A1	03-17-2005	Squibb Bristol Myers Co <i>et al.</i>		
	B10	WO-2005070446-A1	08-04-2005	Scios Inc <i>et al.</i>		
	B11	WO-2006026074-A2	03-09-2006	Univ Duke <i>et al.</i>		
	B12	WO-2006083986-A2	08-10-2006	Us Health <i>et al.</i>		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	10/575,745
				Filing Date	April 9, 2007
				First Named Inventor	Yigal M. Pinto
				Art Unit	1641
				Examiner Name	G. W. Counts
Sheet	3	of	6	Attorney Docket Number	BYG-101

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	Ahmed <i>et al.</i> (2007) "Advanced glycation endproducts: what is their relevance to diabetic complications?" <u>Diabetes, Obesity and Metabolism</u> 9(3): 233-245.	
	C2	Aragno <i>et al.</i> (2005) "Up-Regulation of Advanced Glycated Products Receptors in the Brain of Diabetic Rats is Prevented by Antioxidant Treatment," <u>Endocrinology</u> 146(12): 5561-5567.	
	C3	Aragno <i>et al.</i> (2006) "Oxidative Stress-Dependent Impairment of Cardiac-Specific Transcription Factors in Experimental Diabetes," <u>Endocrinology</u> 147(12): 5967-5974.	
	C4	Bender MedSystems product information and manual for enzyme-linked immunosorbent assay for quantitative detection of human Galectin-3, BMS279/2, dated August 24, 2006, 32 pages.	
	C5	Bohlender <i>et al.</i> (2005) "Advanced glycation end products and the kidney," <u>American Journal of Physiology: Renal Physiology</u> 289: F645-F659.	
	C6	Cameselle-Teijeiro <i>et al.</i> (2005) "Cystic Tumor of the Atrioventricular Node of the Heart Appears to Be the Heart Equivalent of the Solid Cell Nests (Ultimobranial Rests) of the Thyroid," <u>American Journal of Clinical Pathology</u> 123(3): 369-375.	
	C7	Cheng Weng <i>et al.</i> (2007) "Differential neuroprotective effects of a minocycline-based drug cocktail in transient and permanent focal cerebral ischemia," <u>Experimental Neurology</u> 204(1): 433-442.	
	C8	Iurisci <i>et al.</i> (2000) "Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients," <u>Clinical Cancer Research</u> 6:1389-1393.	
	C9	Kankova <i>et al.</i> (2005) "Haplotype analysis of the RAGE gene: identification of a haplotype marker for diabetic nephropathy in type 2 diabetes mellitus," <u>Nephrology, Dialysis, Transplantation</u> 20(6): 1093-1102.	
	C10	Karlsen <i>et al.</i> (2006) "Immune-mediated beta-cell destruction in vitro and in vivo - A pivotal role for galectin-3," <u>Biochemical and Biophysical Research Communications</u> 344(1): 406-415.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	10/575,745
				Filing Date	April 9, 2007
				First Named Inventor	Yigal M. Pinto
				Art Unit	1641
				Examiner Name	G. W. Counts
Sheet	4	of	6	Attorney Docket Number	BYG-101

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C11	Liehn <i>et al.</i> (2005) "CCR5-but not CCR1-deficiency protects against neointima formation in apolipoprotein E-deficient mice," <u>European Heart Journal</u> 26(Suppl 1): 239.	
	C12	Lok <i>et al.</i> (2007) "Galectin-3, a Novel Marker of Macrophage Activity, Predicts Outcome in Patients with Stable Chronic Heart Failure," <u>Journal of the American College of Cardiology</u> 49(9) Suppl. A: 98A.	
	C13	Mensah-Brown <i>et al.</i> (2006) "Functional Capacity of Macrophages Determines the Induction of Type 1 Diabetes," <u>Annals of the New York Academy of Sciences</u> 1084: 49-57.	
	C14	Mita <i>et al.</i> (2007) "Swings in blood glucose levels accelerate atherogenesis in apolipoprotein E-deficient mice," <u>Biochemical and Biophysical Research Communications</u> 358(3): 679-685.	
	C15	Moore <i>et al.</i> (2005) "Using Peripheral Blood Mononuclear Cells to Determine a Gene Expression Profile of Acute Ischemic Stroke: A Pilot Investigation," <u>Circulation</u> 111(2): 212-221.	
	C16	Papaspyridonos <i>et al.</i> (2006) "A Potential Role for Galectin-3 in Atherosclerotic Plaque Progression through Monocyte Chemoattraction and Macrophage Activation" <u>Atherosclerosis</u> 186(2): S3.	
	C17	Pieters (2006) "Inhibition and Detection of Galectins," <u>Chem Bio Chem</u> 7:721-728.	
	C18	Pugliese <i>et al.</i> (2006) "Increased Glomerular Cell (Podocyte) Apoptosis in Rats with Streptozotocin-induced Diabetes Mellitus: Relation to Increased p53 Expression," <u>Diabetologia</u> 49(Suppl 1): 651-652.	
	C19	Reifenberg <i>et al.</i> (2007) "Interferon-gamma Induces Chronic Active Myocarditis and Cardiomyopathy in Transgenic Mice," <u>American Journal of Pathology</u> 171(2): 463-472.	
	C20	Schroen <i>et al.</i> (2003) "Genomic analysis identifies Thrombospondin-2 as a molecular predictor of heart failure," <u>Circulation</u> 108(17 Suppl.):IV-260.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	10/575,745
				Filing Date	April 9, 2007
				First Named Inventor	Yigal M. Pinto
				Art Unit	1641
				Examiner Name	G. W. Counts
Sheet	5	of	6	Attorney Docket Number	BYG-101

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	C21	Schroen <i>et al.</i> (2007) "Lysosomal Integral Membrane Protein 2 is a Novel Component of the Cardiac Intercalated Disc and Vital for Load-induced Cardiac Myocyte Hypertrophy," <u>Journal of Experimental Medicine</u> 204(5): 1227-1235.		
	C22	Sharma <i>et al.</i> (2003) "Galectin-3 is a novel macrophage derived mediator of cardiac fibrosis and specifically marks failing hearts," <u>Circulation</u> 108(17 Suppl.):IV-260.		
	C23	Sharma <i>et al.</i> (2004) "Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction," <u>Circulation</u> 110:3121-3128.		
	C24	Sharma <i>et al.</i> (2005) "Early growth regulator-1 mediates galectin-3 induced cardiac fibrosis," <u>Hypertension</u> 46(4): 819-820.		
	C25	Sharma <i>et al.</i> (2005) "Mice lacking galectin-3 exhibit preserved cardiac function and decreased fibrosis following angiotensin II infusion," <u>Circulation</u> 112(17) Suppl S: II-64.		
	C26	Sharma <i>et al.</i> (2007) "Novel Anti-inflammatory Mechanisms of Ac-SDKP in High Blood Pressure-induced Target Organ Damage," <u>Circulation</u> 114(18) Suppl S: 240.		
	C27	Shirakata <i>et al.</i> (2001) Inverse regulation of the angiogenesis factor VEGF and the angiogenesis inhibitors Thrombospondin-1 and TSP-2 in human epidermal keratinocytes," <u>Journal of Investigative Dermatology</u> 117(2):391.		
	C28	Stitt <i>et al.</i> (2005) "Impaired Retinal Angiogenesis in Diabetes: Role of Advanced Glycation End Products and Galectin-3," <u>Diabetes</u> 54(3): 785-794.		
	C29	Tan <i>et al.</i> (2007) "AGE, RAGE and ROS in Diabetic Neuropathy," <u>Seminars in Nephrology</u> 27(2): 130-143.		
	C30	Tang <i>et al.</i> (2007) "National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines; Clinical Utilization of Cardiac Biomarker Testing in Heart Failure," <u>Circulation</u> 116(5): e99-e109.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	10/575,745
				Filing Date	April 9, 2007
				First Named Inventor	Yigal M. Pinto
				Art Unit	1641
				Examiner Name	G. W. Counts
Sheet	6	of	6	Attorney Docket Number	BYG-101

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C31	van Kimmenade <i>et al.</i> (2005) "Galectin-3 predicts 60 days mortality in heart failure: A step towards multimarker strategy in heart failure. Results from the ProBNP investigation of dyspnea in the emergency department (PRIDE) study," <u>Circulation</u> 112(17) Suppl S: II-669.	
	C32	van Kimmenade <i>et al.</i> (2006) "Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart Failure," <u>Journal of the American College of Cardiology</u> 48(6):1217-1224.	
	C33	Walton <i>et al.</i> (2003) "Thrombospondin-2 and lymphotoxin-alpha gene variations predict coronary heart disease in a large prospective study," <u>Circulation</u> 108(17 Suppl.):IV-260.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.